# A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

> **NCT03930953** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Celgene** · enrollment: 438 (estimated)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** CC-99282
- **DRUG:** Rituximab
- **DRUG:** Obinutuzumab
- **DRUG:** Tafasitamab
- **DRUG:** Valemetostat

## Key facts

- **NCT ID:** NCT03930953
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-05-20
- **Primary completion:** 2027-04-07
- **Final completion:** 2028-02-09
- **Target enrollment:** 438 (ESTIMATED)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03930953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03930953, "A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03930953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*